Stock Exchange Intimations
- USFDA Approval of NDA IMKELDI (Imatinib Oral Solution) filed by our partner Shorla Oncology developed by our JV Oncosol Limited
- Indian Regulatory Authority - SEC approval for conducting Phase III Clinical trials for Recombinant Human Albumin (rHA) 20%
- Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Nifedipine
- Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Octreotide
- Analysts/Investors Call - Call recording 14November2024
- Monitoring Agency Report for the quarter ended 30 September, 2024
- BM intimation
- BM outcome
- Shilpa Medicare announces acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate (OLC)
- Conclusion of USFDA Inspection of Shilpa Medicare Ltd, Unit VI, Bengaluru, Karnataka
- Shilpa Medicare Limited CDMO customer receives Fast-Track Designation for its investigational drug candidate
- Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Desmopressin
- Intimation of Closure of Trading Window
- Disclosure under Regulation 31 of SEBI (SAST) Regulations,2011 (Pledge)
- Disclosure under Regulation 31 of SEBI (SAST) Regulations,2011 (Pledge)
- Appointment of Dr.Sridevi Khambhampaty, as CEO of Shilpa Biologicals Private Limited
- Release of Non Disposal Undertaking (NDU) by certain identified promoters of the Company
- Submission of NDA to U.S. FDA by Unicycive - 1st Regulatory submissions from CDMO partnered projects
- USFDA Approval for Bortezomib Injection NDA 212782
- Shilpa Medicare announces successful outcome of Phase 3 studies of SMLNUD07 – NorUDCA
- Redemption of “NCD” by “SBPL” and partial redemption of NCD by “SPL”
- Monitoring Agency Report for the quarter ended 30thJune, 2024
- Board meeting outcome dated 08thAug 2024
- SML First Indian company to Successfully Complete Phase 1 Clinical Trial for Recombinant Human Albumin (rHA) 20%
- CEP Received from EDQM for SPL API Unit on Ursodeoxycholic Acid
- SPL - Unit - II, Raichur, Karnataka has cleared the COFEPRIS-Mexico GMP inspection
- First international Market Approval for Adalimumab in Morocco
- SPL - Unit 2 Raichur cleared the ANVISA-Brazil GMP inspection
- Allotment of Equity shares by Shilpa Biologicals Pvt. Ltd
- Analysts / Investors’ call 05thJul 2024
- Important milestone for the CDMO business of Shilpa Medicare Limited 04thJul 2024
- Type IV DMF (Drug Master File) of recombinant Human Albumin 20% 04thJune 2024
- Revised Intimation-Revised rating of India Ratings & Research (Ind-Ra)-issued the Long-Term Issuer Rating at ‘IND A+’ 03rdJul 2024
- Credit Rating of Shilpa Pharma Lifesciences Limited 03rdJul 2024
- USFDA Inspection Close-out of Bio-Analytical Laboratory, Unit 7 25thJune 2024
- Keshav Bhutada – Executive Director of SPL & Remuneration to Mr. Madhav Bhutada in Shilpa BiocarePvt Ltd.
- Intimation for Participation in Investor Conference 12thJune 2024
- Analysts_Investors Call - Call recording 24thJune 2024
- Clinical trial Announcement for SML 007 14thMay 2024
- NCLT Order on STPL Merger 03rdMay 2024
- Launch of Pemetrexed Injection, 100mg/10 ml, 500 mg/50 ml, 1000 mg/100 ml - NDA 18thApr 2024
- Europe GMP Approval of Shilpa Medicare Ltd. Unit 4, Jadcherla, Telangana 16thApr 2024
- SE Intimation on Outcome of the meeting of the Securities Issue Committee
- SE intimation for determination of Issue Price
- Declaration of Postal Ballot Results 14 03.24
- Intimation U/R 30 of the SEBI(LODR) Regulations01.03.24
- Intimation UR 30 of the SEBI(LODR) Regulations 26.02.24
- Intimation under Reg 31A (8) ( c)
- Intimation UR Regulation 31A (8) (c) of SEBI (LODR) Regulations, 2015
- Investor Presentation of the Company for the Quarter ended 31 December 2023
- Board Meeting Outcome - 8.2.2024.pdf
- Investor call intimation 06.02.24
- Declaration of Postal Ballot Results 06.02.24
- Intimation UR 30 of the SEBI(LODR) Regulations 06.02.24
- Intimation under Regulation 29(2) Regulations, 2015 05.02.24
- Intimation U/R Regulation 29 of the SEBI (LODR) Regulations
- Intimation UR 30 of the SEBI(LODR) Regulations 27.01.24
- Intimation under Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015
- Europe Approval for Amifampridine Tablets
- Grant of Code “J” for Pemetrexed Injection
- Intimation of closure of Trading Window
- Intimation U/R 30 of the SEBI(LODR) Regulations 12th Dec, 2023
- Intimation U/R 30 of SEBI (LODR) Regulations 16th Nov, 2023
- Investors Call Outcome 11th Nov, 2023
- Intimation under 31A of the SEBI (LODR) Regulations 10th Nov, 2023
- Board Meeting Outcome 10th Nov, 2023
- Intimation U/R 30 of the SEBI(LODR) Regulations 10th Nov, 2023
- Intimation of Board Meeting 03nd Nov, 2023
- Intimation U/R 30 of the SEBI(LODR) Regulations 02nd Nov, 2023
- Intimation U/R 30 of the SEBI(LODR) Regulations 17th Oct, 2023
- Intimation U/R 30 of the SEBI(LODR) Regulations 11th Oct, 2023
- Intimation of closure of Trading Window
- Voting Results and Scrutinizer Report of 36th Annual General Meeting as per Regulation
- Intimation U/R 30 of the SEBI(LODR) Regulations 01st Sept, 2023
- Intimation U/R 30 of the SEBI(LODR) Regulations 01st Sept, 2023
- Declaration of Postal Ballot Results 29th Aug, 2023
- Declaration of Postal Ballot Results 31st July, 2023
- Intimation U/R 30 of the SEBI(LODR) Regulations
- Outcome of the meeting of Board of Directors 10th Aug, 2023
- Intimation under Reg. 30 (LODR)- 31st July, 2023
- Postal Ballot Notice – Disclosure under Reg.30
- Outcome of the meeting of Board of Directors held on 21th July 2023
- Intimation under Reg. 30 (LODR)- 04thJuly, 2023 Newspaper Publication
- Intimation of Closure of Trading Window
- Outcome of the meeting of Board of Directors 23rd June, 2023
- Outcome of the meeting of Board of Directors 25th May, 2023
- Prior Intimation uR 29 Final Intimation U/R of the SEBI ( LODR) Regulations
- Intimation U/R 30 of the SEBI(LODR) Regulations
- Intimation U/R 30 of the SEBI(LODR) Regulations
- Intimation of Board Meeting under Regulation 29 of SEBI
- Intimation under Reg. 30 (LODR)- 11th Mar, 2023
- Intimation under Reg. 30 (LODR)- 28th Mar, 2023
- Intimation under Reg. 30 (LODR)- 13thFeb, 2023
- Intimation under Reg. 30 (LODR)- 15thFeb, 2023 Inverstors Presentation
- Intimation under Reg. 30 (LODR)- 16thFeb, 2023
- Intimation under Reg. 30 (LODR)- 21stFeb, 2023
- Intimation under Reg. 30 (LODR)- 16thFeb, 2023
- News Paper Publication - 15thFeb, 2023
- Board Meeting Outcome 14th Feb, 2023
- Credit Rating
- Intimation under Reg. 30 (LODR) - 10th Apr, 2023 Intimation under Reg. 30 (LODR)- 16thDec, 2022
- Intimation under Reg. 30 (LODR)- 30thNov, 2022
- Intimation under Reg. 30 (LODR)- 21stNov, 2022
- Intimation under Reg. 30 (LODR)- 17thNov, 2022
- Intimation under Reg. 30 (LODR)- 14thNov, 2022 Newspaper Publication
- Intimation under Reg. 30 (LODR)- 13thNov, 2022
- Intimation under Reg. 30 (LODR)- 12thNov, 2022
- Intimation under Reg. 30 (LODR)- 03rdNov, 2022
- Intimation under Reg. 30 (LODR)- 28thOct, 2022
- Intimation under Reg. 30 (LODR)- 22ndOct, 2022
- Intimation under Reg. 30 (LODR)- 06thOct, 2022 Newspaper Publication
- Intimation under Reg. 30 (LODR)- 28thSep, 2022
- Intimation under Reg. 30 (LODR)- 26thSep, 2022
- Intimation under Reg. 30 (LODR)- 19thSep, 2022
- Intimation under Reg. 30 (LODR)- 16thSep, 2022
- Intimation under Reg. 30 (LODR)- 08thSep, 2022
- Intimation under Reg. 30 (LODR)- 30thAug, 2022
- Intimation under Reg. 30 (LODR)- 25thAug, 2022
- Intimation under Reg. 30 (LODR)- 23rdAug, 2022
- Intimation under Reg. 30 (LODR)- 19thAug, 2022
- Intimation under Reg. 30 (LODR)- 13thAug, 2022
- Intimation under Reg. 30 (LODR)- 12thAug, 2022
- Intimation under Reg. 30 (LODR)- 11thAug, 2022
- Intimation under Reg. 30 (LODR)- 27thJun, 2022
- Intimation under Reg. 30 (LODR) - 31st May, 22
- Intimation under Reg. 30 (LODR) - 25th May, 22
- Intimation under Reg. 30 (LODR) - 02nd May, 22
- Intimation under Reg. 30 (LODR) - 25th Apr, 22
- Intimation under Reg. 30 (LODR) - 02nd Apr, 22
- Launch of new brand Capebel (Capecitabine 1000 MG dispersible tablet)
- Outcome of the Investors Analysts meet Dated 14th Nov, 2022
- Announcement under Reg.30(lodr) Newspaper Publication Dated 13th Nov, 2022
- Appointment of o3 Capital Global Advisory Private Limited
- Report on Voilation
- Outcome of 35th Annual General Meeting
- Cessation of Directorship of Ms. Sirisha Chintapalli on account of completion of tenure
- Intimation of closure of Trading Window
- Voting Results and Scrutinizer Report of 35th Annual General Meeting
- Intimation of Newspaper Publication - E-voting results of 35th AGM
- Intimation under Reg. 30 (LODR) - 22nd Sep, 2022
- Intimation under Reg. 30 (LODR) - 19th Sep, 2022
- Intimation under Reg. 30 (LODR) - 16th Sep, 2022
- Intimation under Reg.34 and 42 of SEBI (LODR) - Notice of 35th AGM and Annual Report
- Newspaper Publication of dispatch of Notice of 35th Annual General Meeting (AGM)
- Book Closure Date and Record Date - 35th AGM
- Clarification with regard to query on shareholding pattern for the quarter ended 30th Jun, 2022
- Intimation of the Investors Analysts meet scheduled on 24th Aug, 2022
- Outcome of the Investors Analysts meet dt 24th Aug, 2022
- Intimation UR 30 - 19th Aug, 2022
- Book Closure Date & Record Date – 35th AGM
- Announcement under Reg. 30 (LODR) Newspaper Publication dt.13.08.2022
- Outcome of BM 33, 36 & 42 - 11th Aug, 2022
- Intimation UR 30 - 29th Jul, 2022
- Intimation UR 30 - 16th Jul, 2022
- Intimation UR 30 - 12th Jul, 2022
- Appointment of Dr Kamal K Sharma as an Additional Independent Director - 1st July, 2022
- SE Intimation on Slump Sale - 1st July, 2022
- Trading window closure notice - 1st July, 2022
- Intimation UR 30 - 27rd June, 2022
- Board Meeting Outcome to Stock Exchanges 23rd May, 2022
- Prior Intimation UR 29 16th May, 2022
- SE intimation on Slump Sale 2nd April, 2022
- Resignation of CS 16th March, 2022
- Credit Rating 7th March, 2022
- Press Release 11th Fab, 2022
- SE Intimation of Resignation of Directors 09th Fab, 2022
- Update on slump sale_SE Intimation 09th Fab, 2022
- INTIMATION UR 30 21st Jan, 2022
- INTIMATION UR 30 19th Nov, 2021
- INTIMATION UR 30 24th Sep, 2021
- Outcome of BM 30 14th Aug, 2021
- Corrigendum And Update 13th Aug, 2021
- INTIMATION UR 30 29th July, 2021
- INTIMATION UR 30 28th July, 2021
- OUTCOME UR 30 12th July, 2021
- INTIMATION UR 30 25nd June, 2021
- INTIMATION UR 30 22nd June, 2021
- INTIMATION REG 30 28th May, 2021
- INTIMATION BM 24th May, 2021
- INTIMATION DIVIDEND 25th May, 2021
- INTIMATION REG 30 17th May, 2021
- INTIMATION REG 30 26th April, 2021
- CLOSURE OF TRADING WINDOW 31st Mar, 2021
- UR 30 - MEETING UPDATES 31st Mar, 2021
- INTIMATION UR 30 05th Mar, 2021
- Intimation Swatchshil 04th Mar, 2021
- Investor Notification, 18th Feb, 2021
- INTIMATION UR 30, 18th Feb, 2021
- INTIMATION REG 30, 15th Feb, 2021
- INTIMATION REG 30, 13th Feb, 2021
- CFO Resignation 19th Jan, 2021
- Closure Of Trading Window 30th Dec, 2020
- Credit Rating 15th Dec, 2020
- US FDA 10th Oct, 2020
- Amit Chander Resignation 02nd Oct, 2020
- Related Party Transactions U/R 23(9) 30th Sep, 2020
- Outcome Of BM 09th Sep, 2020
- Investors Meeting Outcome
- Investors Meeting Intimation
- INTIMATION REG 30
- Outcome Of BM
- Intimation 29
- INTIMATION REG 30
- DECLARATION
- Outcome Of BM
- Intimation 29
- Intimation UR 30
- Outcome Of BM UR 30
- Compliance Certificate Half Year
- Intimation UR 30
- Intimation UR 30 – 18th April, 2020
- Intimation UR 30 – 6st April, 2020
- Intimation UR 30 – 1st April, 2020
- Closure Of Trading Window
- Proceedings OF EGM
- Voting Results
- Facility For Attending Egm
- Intimation Of Record Date Interim Dividend
- Outcome Of BM UR 30 – 6st March, 2020
- Closure Of Trading Window For Dividend
- Intimation UR 29
- Intimation UR 30 – 26th Feb, 2020
- Intimation R30
- Intimation R30 - Outcome of Board Meeting
- Stock Exchange Intimation_30 – 08th Feb, 2020
- Intimation UR 30 – 31st Jan, 2020
- Intimation UR 30 – 31st Jan, 2020
- Intimation R30 Pirfenidone
- Intimation R30 Lenvatinib
- Company Upadate Lenvatinib
- Intimation Of UR 29
- BM Intimation Feb 10
- Intimation_UR_30_ 04-12-2019
- Outcome of Board meeting_09-11-2019
- Board meeting Intimation_09-11-2019
- Intimation_UR_30_ 25-10-2019
- Intimation U/R 30 on 05-10-2019_sw
- Book Closure Intimation 31stAGM
- Scrutinizers Report 31stAGM
- E-Voting Results 30thAGM
- Scrutinizer Report 30thAGM
- Intimation U/R 30 SEBI(LODR) 07.09.2019
- Intimation U/R 30 on 16-05-2019 sw
- Intimation U/R 30 on 17-05-2019 sw
- Intimation U/R 30 of the SEBI(LODR) Regulations- Reg. - (USFDA ANDA sw)
- Intimation U/R 30 of the SEBI(LODR) Regulations- Reg. - (USFDA Voluntary action initiated sw)
- Intimtion under regulation 30 SEBI (LODR) 2015
- Outcome under regulation 30 SEBI (LODR) 2015 on 07th Feb 2019
- BSE-Intimation of BM on 13th Feb 2018
- BSE-Intimation of BM on 29th May 2017
- BSE-Intimation of BM on 9th March 2017
- BSE-Record Date on 6th March 2017
- BSE-Intimation of BM on 06th March 2017
- BSE-Intimation of BM on 31st Jan 2017
- BSE-Intimation of BM on 17th Aug 2016
- NSE-Intimation of BM on 17th Aug 2016
For any queries / grievance, Please Contact:
- Name
- Ms. Ritu Tiwary
- Designation
- Company Secretary & Compliance Officer
- Address
- #12-6-214/A1,
Hyderabad Road,
Raichur – 584 135,
Karnataka, India. - Telephone No.
- 08532 - 238704
- Fax
- 08532 - 238876
- [email protected]
- CIN No.
- L85110KA1987PLC008739